Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2010
Date:11/4/2010

CARLSBAD, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended September 30, 2010.  The Company finished the third quarter of 2010 with a pro forma net operating loss (NOL) of $6.0 million and $23.1 million for the three and nine months ended September 30, 2010, respectively, compared to a pro forma net operating loss of $6.9 million and $6.1 million for the same periods in 2009.  On a GAAP basis, Isis reported a loss from operations of $8.9 million and $32.5 million for the three and nine months ended September 30, 2010, respectively, compared to $10.4 million and $15.9 million for the same periods in 2009.  

"In 2010, our most notable accomplishment is the completion of two more positive Phase 3 studies of mipomersen.  The successful completion of the Phase 3 program for mipomersen to support our initial market brings us closer to the commercialization of a first-in-class drug for patients who are in desperate need of new therapies.  Genzyme is on track to file for marketing approval of mipomersen in both the U.S. and Europe in the first half of next year.  We believe that the initial market for mipomersen represents a significant financial opportunity, and we are excited to bring this new medicine to an underserved patient population," said B. Lynne Parshall, COO and CFO of Isis.  

"We continue to maintain a strong financial position in large part due to our partnership successes that have continued to generate new revenue for us.  For example, our 2010 revenue includes the amortization of upfront fees from our new collaboration with GSK and new sublicensing revenue from Regulus' alliance with sanofi-aventis.  In addition, we have earned $13 million in milestone payments from our partners.  We earned many of these mileston
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Calif. , Oct. 17, 2014  Amgen (NASDAQ: ... R. Sanders Williams , M.D., president of Gladstone ... Distinguished Professor.  "We are pleased to ... Board," said Robert A. Bradway , chairman and ... distinguished experience in academic medicine and his direct experience ...
(Date:10/17/2014)... 2014 According to ... Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic ... Neurology, Oncology, Cardiology) - Global Forecasts to ... Optical Imaging market over the forecast period ... $917.1 million in 2014 and is expected ...
(Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... Orthopedic Group, Inc. (NYSE: HGR ) today announced that ... private offering to qualified institutional buyers pursuant to Rule 144A under ... Regulation S under the Securities Act.  The notes were priced at ... expected to close on November 2, 2010. The notes ...
... Md. and INDIANAPOLIS, Oct. 20 MacroGenics, Inc. and ... today announced that the Protege Data Monitoring Committee (DMC), ... and biostatistics, has completed a planned analysis of one-year ... clinical trial of teplizumab, an investigational biologic under development ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes 2Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes 3MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint 2MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint 3
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 JZ ... expertise, nutritional coaching, corporate wellness programming, authorship, international lecturing ... is excited to announce the release of the JZ ... After many years of coaching thousands of individuals on ... tracking app that does not require calorie counting or ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Rockynol ... Living Center on Oct. 14. The $11 million project ... services, and a cooked-to-order kitchen with full-service restaurant style ... premier choice for first class Assisted Living apartments,” said ... residents deserve the highest quality of care and this ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/19/2014)... 20, 2014 Hastings and Hastings, a ... of service throughout the greater Phoenix area and across ... with regard to catastrophic automobile accidents. Statistics have indicated ... and throughout Arizona. As such, Hastings and Hastings has ... representation for those who have been injured through no ...
(Date:10/19/2014)... Having been working in the garment industry for ... needs. According to James, one of the company’s top designers, ... with high-low skirts that add beauty to them. Chiffon floor ... has unveiled its new selection of 2014 long prom dresses. ... new items are available in over 20 popular designs. The ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... second consecutive year, Omega Institute will host an important conference at ... spectrum disorders, to explore the latest research and development in treating ... ... August 1, 2008 -- For the second consecutive year, Omega ...
... Alexandria, VA A new invited article in the ... Neck Surgery calls on the U.S. medical community ... physicians who care for patients, victims, and casualties of ... , The article, authored by the American Academy of ...
... Life,Sciences, Inc. (Nasdaq: CALP ) today announced ... Tools Roundtable Conference in Boston,Massachusetts, will be webcast ... Hrusovsky, President and CEO of Caliper, will be ... webcast can be accessed at, http://www.wsw.com/webcast/leerink17/calp/ . An ...
... access" or free online, they get read more often, ... get cited more often in academic literature, finds a ... Philip Davis and colleagues, including three Cornell professors, is ... they need to relevant articles. , "It appears that ...
... Data for Second ... Quarter 2008 ... July 31 Sunrise Senior Living,Inc. (NYSE: SRZ ) today announced that ... the Securities and Exchange Commission,("SEC"). The Company also reported preliminary selected financial and,operating ...
... Conference Call Today at 5:00 p.m. Eastern Time ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... corporate progress and financial results,for the second quarter ... focus are to develop picoplatin as an oncology,platform ...
Cached Medicine News:Health News:Omega to Hold Conference: Autism Through the Life Span II 2Health News:Omega to Hold Conference: Autism Through the Life Span II 3Health News:Free articles get read but don't generate more citations 2Health News:Sunrise Files 2007 Form 10-K 2Health News:Sunrise Files 2007 Form 10-K 3Health News:Sunrise Files 2007 Form 10-K 4Health News:Sunrise Files 2007 Form 10-K 5Health News:Sunrise Files 2007 Form 10-K 6Health News:Sunrise Files 2007 Form 10-K 7Health News:Sunrise Files 2007 Form 10-K 8Health News:Sunrise Files 2007 Form 10-K 9Health News:Sunrise Files 2007 Form 10-K 10Health News:Sunrise Files 2007 Form 10-K 11Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 2Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 3Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 4Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 5Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 6Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 7Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 8Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 9
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
... The Finnpipette BioControl ... innovative features as the ... universal handle fits all ... single channel tip cone ...
... best value in high performance electronic pipetting!, ... lightweight design reduce hand fatigue and strain ... tip ejector , Color coding for easy ... for greater performance use Hamilton AdvanTip Low ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
Medicine Products: